Riskpilot← Back to searchSign inGet full accessCalliditas Therapeutics AB
ABActiveOrg 5566599766Kungsbron 1Research and experimental development on natural sciences and engineering · NACE 7210Est. 200420-49 employees
Revenue 2025
SEK 2B
+143% vs 2023
EBITDA margin
-6.8%
+21% vs 2023
Equity ratio
6.7%
Financial strength
Net profit 2025
SEK -629,4M
-130% vs 2023
| Revenue | SEK 2B | +143% |
| EBITDA | SEK -132,3M | +21% |
| Net profit | SEK -629,4M | -130% |
| Total assets | SEK 2,4B | +7% |
| Equity | SEK 162M | -82% |
| Employees | — | — |
Legal name
Calliditas Therapeutics AB
Org number
5566599766
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
15 april 2004
Share capital
SEK 2 398 000
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska, direkt eller genom dotterbolag, bedriva forskning och utveckling samt tillverkning och försäljning av läkemedel och medicintekniska produkter, äga och förvalta aktier och andra värdepapper samt annan lös och fast egendom, samt därmed förenlig verksamhet.
Address
Kungsbron 1
Phone
+4684113005
Email
info@calliditas.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|
| Revenue | 874 | 229 347 | 548 977 | 805 551 | 1 958 890 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −352 567 | −355 717 | −215 364 | −167 796 | −132 292 |
| Depreciation & amort. | — | — | — | — | — |
| EBIT | −352 567 | −355 717 | −215 364 | −167 796 | −132 292 |
| Net financials | −110 155 | −833 | 1 942 | −183 684 | −942 048 |
| Profit before tax | −407 363 | −354 405 | −208 548 | −273 518 | −629 376 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −407 363 | −354 405 | −208 548 | −273 518 | −629 376 |
| Item | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 318 525 | 1 528 439 | 2 173 639 | 2 255 130 | 2 404 112 |
| Equity | 1 235 069 | 1 208 303 | 1 130 956 | 909 774 | 161 955 |
| Long-term debt | 105 | 189 269 | 717 485 | 981 918 | 1 534 915 |
| Short-term debt | 78 379 | 121 792 | 315 686 | 363 438 | 707 242 |
| Total debt | 78 484 | 311 061 | 1 033 171 | 1 345 356 | 2 242 157 |
EBITDA margin
-6.8%
This company
15.8%
Market median
-143% vs market
20202025
Equity ratio
6.7%
This company
38.2%
Market median
-82% vs market
20202025
Return on equity
-388.6%
This company
18.4%
Market median
-2212% vs market
20202025
Net profit margin
-32.1%
This company
8.1%
Market median
-496% vs market
20202025
Asset turnover
0.81×
This company
1.12×
Market median
+28% vs market
20202025
Debt / equity
13.84×
This company
0.62×
Market median
-2132% vs market
20202025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-01-01 – 2025-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AL Chief Auditor | Chief Auditor | 2025 |
CF Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (4) | ||
FO Chief Auditor | Chief Auditor | 2020 – 2022 |
RJ Chief Executive Officer | Chief Executive Officer | 2020 – 2024 |
AK Chief Auditor | Chief Auditor | 2023 – 2023 |
JT Chief Auditor | Chief Auditor | 2022 – 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Former (12) | ||
| Board of Directors | 2020 – 2024 | |
| Board of Directors | 2020 – 2024 | |
| Board of Directors | 2024 – 2025 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2024 – 2024 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2020 – 2020 | |
| Board of Directors | 2022 – 2024 | |
| Chairman | 2020 – 2024 | |
| Board of Directors | 2020 – 2024 | |
| Board of Directors | 2023 – 2023 | |
| Board of Directors | 2022 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ASAHI KASEI CORPORATION
Calliditas Therapeutics AB (this company)CALLIDITAS THERAPEUTICS FRANCE SASCALLIDITAS THERAPEUTICS NA ENTERPRICE INC.Calliditas Therapeutics France SasCALLIDITAS THERAPEUTICS US INC.Calliditas Na Enterprises Inc.Calliditas Therapeutics Us Inc.Calliditas Therapeutics Na Enterprice Inc.Board members of Calliditas Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Linnea Franke | Chief Auditor | 0 companies |
| Fredrik Oskar Norrman | Chief Auditor | 0 companies |
| Renée Julie E Aguiar Lucander | Chief Executive Officer | 0 companies |
| Carl Fredrik Johansson | Chief Executive Officer | 0 companies |
| Anna Kristina Svanberg | Chief Auditor | 0 companies |
| Jakob Tomas Christoffer Grunditz | Chief Auditor | 0 companies |
| Hilde Furberg | Board of Directors | 0 companies |
| Frederick William Driscoll | Board of Directors | 0 companies |
| Masaya Eto | Board of Directors | 0 companies |
| Stig Lennart Hansson | Board of Directors | 0 companies |
| Mark Earl Hensley | Chairman | 0 companies |
| Thomas Lennart Eklund | Board of Directors | 0 companies |
| Stacy Gibson Wheeler | Board of Directors | 0 companies |
| Bengt Åke Julander | Board of Directors | 0 companies |
| Karl Henrik Stenqvist | Board of Directors | 0 companies |
| Yoshikazu Aoki | Deputy Board Member | 0 companies |
| Elmar Josef Schnee | Chairman | 0 companies |
| Diane Louise Parks | Board of Directors | 0 companies |
| Molly Henderson | Board of Directors | 0 companies |
| Margareta Elisabeth Björk | Board of Directors | 0 companies |